The Business Times
The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

SUBSCRIBERS

Amgen's new cholesterol drug falls short as sales driver

Biotech giant is anxious for Repatha to make up for slowing sales of older ones

Published Thu, Apr 27, 2017 · 09:50 PM
Share this article.

San Francisco

AMGEN Inc's new cholesterol drug is still struggling to gain traction, missing analysts' estimates at a time when the biotechnology giant is anxious for its newer drugs to make up for slowing sales of its older ones.

Sales of the drug, called Repatha, for the first quarter were US$49 million, the company said on Wednesday.

That was far short of the US$71.6 million average of analysts' es…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here